Hernández-Sarmiento R, Bustamante-Gómez L, Lesport-Castro LP, Nassar-Mendoza N, Méndez-Rodríguez I

Language: Spanish
References: 24
Page: 13-17
PDF size: 236.58 Kb.

ABSTRACT

Objective: To determine the prevalence of community-acquired methicillin-resistant Staphylococcus aureus (MRSA-AC) in a risk population in Bogotá, Colombia, and to analyze the profile of susceptibility to alternative antimicrobials to vancomycin for the treatment of infections with this microorganism. Material and methods: Cross-sectional study in young soccer players. Ninety-one samples of nasal swabs were obtained for microbiological analysis; Resistance to antimicrobial agents was carried out using the Kirby-Bauer method and an epsilometry test (E-test) for the MRSA-CA samples. Results: Of the total samples obtained, only one was positive for MRSA-AC (2%) and 43 for methicillin-sensitive Staphylococcus aureus (SAMS) (48%), which shows the low prevalence of this strain in the population studied. Conclusion: Despite the low prevalence of CA-MRSA strains, it is important to emphasize measures of personal hygiene, including handwashing and wound care that result from sports competitions.

REFERENCES

1. Boucher HW, Corey GR. Epidemiology of methicillin resistant Staphylococcus aureus. Clin Infect Dis. 2008; 46(S5): S344-S349.

2. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis. 2001; 7(2): 178-182.

3. Cortés JA, Gómez CA, Cuervo SI, Leal CAL. Implicaciones en salud pública de Staphylococcus aureus meticilino resistente adquirido en la comunidad en Bogotá, Colombia. Rev Salud Publica. 2007; 9(3): 448-454.

4. Tsubakishita S, Kuwahara-Arai K, Sasaki T, Hiramatsu K. Origin and molecular evolution of the determinant of methicillin resistance in staphylococci. Antimicrob Agents Chemother. 2010; 54(10): 4352-4359.

5. Watkins RR, David MZ, Salata RA. Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus. J Med Microbiol. 2012; 61(Pt 9): 1179-1193.

6. Miller LG, Kaplan SL. Staphylococcus aureus: a community pathogen. Infect Dis Clin North Am. 2009; 23(1): 35-52.

7. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T et al. New insights into meticillin-resistant Staphylococcus aureus [MRSA] pathogenesis, treatment and resistance. Int J Antimicrob Agents. 2012; 39(2): 96-104.

8. DeLeo FR, Otto M, Kreiswirth BNB, Chambers HFH. Community-associated meticillin-resistant Staphylococcus aureus. Lancet. 2010; 375(9725): 1557-1568.

9. Pottinger PS. Methicillin-resistant Staphylococcus aureus infections. Med Clin North Am. 2013; 97(4): 601-619.

10. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010; 23(3): 616-687.

11. Redziniak DE, Diduch DR, Turman K, Hart J, Grindstaff TL, MacKnight JM et al. Methicillin-resistant Staphylococcus aureus [MRSA] in the Athlete. Int J Sports Med. 2009; 30(08): 557-562.

12. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis. 2003; 36(2): 131-139.

13. Kazakova S, Hageman J, Matava M. A clone of methicillin-resistant. N Engl J Med. 2005; 352: 468-475.

14. Palevencino E. Métodos recomendados para el estudio de susceptibilidad en Staphylococcus aureus, Staphylococcus coagulasa negativa y Staphylococcus saprophyticus: nuevos puntos de corte e interpretación de resultados. Rev Chil Infect. 2002; 19: 119-124.

15. Jaramillo S. Prueba Épsilon [Etest]. Rev CES Med. 1998; 12(1): 34-41.

16. Cockerill F, Patel J, Alder J, Bradford P, Dudley M, Eliopoulos G et al. Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. CLSI document M100-S23 2013; 33(1). Disponible en: https://www.researchgate.net/file.PostFileLoader.html?id=55d77c2f614325f5d38b461b&assetKey=AS:273836702928896@1442299165694

17. Champion AE, Goodwin TA, Brolinson PG, Werre SR, Prater MR, Inzana TJ. Prevalence and characterization of methicillin-resistant Staphylococcus aureus isolates from healthy university student athletes. Ann Clin Microbiol Antimicrob. 2014; 13(1): 33.

18. Jaworski CA, Donohue B, Kluetz J. Infectious disease. Clin Sports Med. 2011; 30(3): 575-590.

19. Teglia O, Regorini E, Otario R. Staphylococcus aureus meticilino-resistente, emergente de la comunidad. Rev Med Rosario. 2007; 73(1): 76-81.

20. Moellering RC. Current treatment options for community? Acquired methicillin? Resistant Staphylococcus aureus infection. Clin Infect Dis. 2008; 46(7): 1032-1037.

21. Grindstaff TL, Saliba SA, Mistry DJ, Macknight JM. Community-associated methicillin-resistant Staphylococcus aureus. N Am J Sports Phys Ther. 2007; 2(3): 138-146.

22. Cohen PR. The skin in the gym: a comprehensive review of the cutaneous manifestations of community-acquired methicillin-resistant Staphylococcus aureus infection in athletes. Clin Dermatol. 2008; 26(1): 16-26.

23. Garza D, Sungar G, Johnston T, Rolston B, Ferguson JD, Matheson GO. Ineffectiveness of surveillance to control Staphylococcus aureus in a professional football team. Ann R Coll Surg Engl. 2007; 89: 668-671.

24. Kirkland EB, Adams BB. Methicillin-resistant Staphylococcus aureus and athletes. J Am Acad Dermatol. 2008; 59(3): 494-502.